• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Science: A Fortnightly Journal of Research >Angiotensin converting enzyme inhibitors in the treatment of hypertension
【24h】

Angiotensin converting enzyme inhibitors in the treatment of hypertension

机译：血管紧张素转换酶抑制剂治疗高血压

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Angiotensin converting enzyme (ACE) catalyses the conversion of angiotensin I (Ang I) to angiotensin II (Ang II). The ACE activity directly related to hypertension as Ang II is the blood pressure regulating hormone. Therefore, ACE inhibitors are a major class of antihypertensive drugs. Captopril, chemical name, was the first orally active ACE inhibitory antihypertensive drug, discovered in 1977. Since then, a number of such drugs have been synthesized. Enzyme-inhibitor bound crystal structural studies reveal a great deal of understanding about the interactions of the inhibitors at the active site of ACE. This can be helpful in the rational design of ACE inhibitors. With the advancement of the combination therapy, it is known that ACE inhibitors having antioxidant activity can be beneficial for the treatment of hypertension. This study describes the development of ACE inhibitors in the treatment of hypertension. Importance of ACE inhibitors having antioxidant activity is also described.
机译：血管紧张素转化酶（ACE）催化血管紧张素I（Ang I）转化为血管紧张素II（Ang II）。与血管紧张素II直接相关的ACE活性是血压调节激素。因此，ACEI抑制剂是一类主要的降压药。卡托普利（化学名称）是第一种口服活性ACE抑制性降压药，于1977年发现。此后，已经合成了许多此类药物。酶抑制剂结合的晶体结构研究揭示了对ACE活性位点上抑制剂相互作用的大量理解。这可能有助于合理设计ACE抑制剂。随着联合疗法的发展，已知具有抗氧化活性的ACE抑制剂可有益于高血压的治疗。这项研究描述了ACE抑制剂在高血压治疗中的发展。还描述了具有抗氧化剂活性的ACE抑制剂的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号